MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Do you or someone you know qualify as an emerging leader in the healthcare industry?
Fill out a nominee form at the below link for a chance to be chosen as one of the 13 winners in Managed Healthcare Executive’s annual Emerging Leaders in Healthcare feature.
The popular human-interest story features healthcare leaders paving the way for the future of their organizations, for healthcare and for others seeking to make a difference in the industry.
This year, editors are searching for a diverse group of healthcare professionals coming from different backgrounds, healthcare sectors, with different interests and so on. Nominees must be early or mid-career healthcare leaders who have worked in the field for 10 years or less.
MHE has featured a number of game-changers in the past. Some can be found in last year’s issue here and the 2022 edition here.
This year’s feature is planned to make its way back to readers in MHE’s August edition.
People selected for the 2024 MHE Emerging Leaders in Healthcare Award will:
To be considered a candidate, those interested must fill out the nominee form here by May 23 at 5 p.m. ET.
After a thorough selection process, editors will select the winners and have them fill out a short questionnaire and sit for a brief video interview.
Good luck!
FDA Updates for the Week of May 6: An Approval, a Delay and Two Ad Comm Meetings
May 11th 2024The FDA has approved a liquid mycophenolate to prevent organ rejections but delayed the approval of Moderna’s RSV vaccine. Regulators have set dates for advisory committee meetings for midomafetamine for PTSD and for donanemab in Alzheimer’s disease. Additionally, the agency has set review dates for a subcutaneous Opdivo and a pancreatic/lung cancer therapy.
Read More